Lifecore Biomedical, Inc. last reported quarterly results on Nov 4, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $25.3 million (-28.0% year over year) and diluted EPS of -$1.08. It usually reports 22–36 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 4, 2027.
Results for Q4 FY2026, the quarter ending around Dec 30, 2026. Expected on a Thursday. Based on how many days after a quarter ends the company has reported recently. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 22–36 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 4, 2026
35 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
25
-28.0%
|
-40
-171.4%
|
-1.08
-157.1%
|
|
Aug 5, 2026
36 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
34
+4.9%
|
-6
+6.3%
|
-0.19
+24.0%
|
|
May 6, 2026
36 days after quarter end
|
Q3 FY2026
ended Mar 31, 2026
|
—
|
—
|
—
|
|
Mar 16, 2026
22 days after quarter end
|
Q2 FY2026
ended Feb 22, 2026
|
—
|
—
|
—
|
|
Nov 6, 2025
37 days after quarter end
|
Q1 FY2026
ended Sep 30, 2025
|
31
+25.9%
|
-10
+38.4%
|
-0.29
+45.3%
|
|
Aug 7, 2025
74 days after quarter end
|
Q4 FY2025
ended May 25, 2025
|
36
-3.8%
|
-1
+83.8%
|
-0.06
+68.5%
|
|
Apr 3, 2025
39 days after quarter end
|
Q3 FY2025
ended Feb 23, 2025
|
35
-1.5%
|
-15
-194.5%
|
-0.42
-200.0%
|
|
Jan 2, 2025
39 days after quarter end
|
Q2 FY2025
ended Nov 24, 2024
|
33
+8.0%
|
-7
-146.2%
|
-0.25
-164.1%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LFCR (Nasdaq)
- Fiscal year ends
- May 25
- Incorporated in
- DE
- Headquarters
- Chaska, MN
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1005286
- Former names
- LANDEC CORP \CA\ (until Nov 7, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.